Scripps New Treatments in Chronic Liver Disease 2020 CME - San Diego

Posted By : User Ref No: WURUR49740 0
  • Image
  • TypeConference
  • Image
  • Location San Diego, California, United States
  • Price
  • Date 20-03-2020 - 22-03-2020
Scripps New Treatments in Chronic Liver Disease 2020 CME - San Diego, San Diego, California, United States
Conference Title
Scripps New Treatments in Chronic Liver Disease 2020 CME - San Diego
Event Type
Conference
Conference Date
20-03-2020 to 22-03-2020
Location
San Diego, California, United States
Organization Name / Organize By
Scripps Health
Organizing/Related Departments
Scripps Health
Organization Type
Event Organizing Company
ConferenceCategory
Both (Technical & Non Technical)
ConferenceLevel
All (State/Province/Region, National & International)
Related Industries

Medical/Healthcare/Hospital

Location
San Diego, California, United States

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases. New treatments which have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) will be discussed by Dr. Kris Kowdley from the Swedish Liver Center in Seattle, WA. We also have invited Dr. Constantine J. Karvellas, Assistant Professor, Division of Gastroenterology, Department of Critical Care Medicine at the University of Alberta to act as our William S. Haubrich Memorial Lecturer on the topic of Acute Liver Failure. The course will also review alcoholic liver disease and NASH, which have now surpassed chronic hepatitis C as the leading indications for liver transplantation in the United States. The first FDA-approved therapy for NASH is anticipated in 2020 and the data supporting this FDA submission will be updated as well as the latest abstracts from AASLD 2019 on NASH. We have also invited a world-recognized expert on alcoholic liver disease to update our knowledge of the topic this year. Our conference will include a lecture on diet and exercise as management and prevention of obesity and fatty liver disease this year. We will also include a lecture on diagnosis and management of benign lesions of the liver given by an expert on this subject. And lastly, there will be a lecture devoted to the use of systemic therapies for hepatocellular carcinoma.

Others Details

Speakers: Paul J. Pockros, MD, FACG, Catherine T. Frenette, MD, FAST, AGAF, Timothy J. Davern, MD, Ken Fujioka, MD, Constantine J. Karvellas, MD, SM, FRCPC, FCCM, Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD, Suthat Liangpunsakul, MD, Yuki Rosenkoetter, PAC, MPAS, Sammy Saab, MD, MPH, AGAF, FAASLD, FACG, Norman L. Sussman, MD, Norah A. Terrault, MD, MPH, John W. Ward, MD Time: 12:30 - 11:30

Registration Fees
Available
Registration Fees Details
Pre-conference Workshop: USD 150.0, Physicians (MD, DO): USD 385.0, Non-Physicians (RN, PA, NP): USD 315.0, Fellows, Residents, Students: USD 210.0
Registration Ways
Website
Address/Venue
  Hilton San Diego Resort and Spa, 1775 East Mission Bay Drive  Pin/Zip Code : 92109
Contact
Scripps Conference Services and CME

[email protected]

   8586786400